Literature DB >> 9041680

Tissue distribution and metabolism in rat of an ethynesulphonamide with filaricidal activity.

N Radembino1, M C Dessalles, J H Trouvin, P M Loiseau, P Gayral, G Mahuzier, M Rapp, P Labarre, D Godeneche, J C Madelmont, J C Maurizis, A Veyre, J L Chabard.   

Abstract

1. The tissue distribution and metabolism of a new filaricidal agent P903 (N-[(2-phenylethynyl)sulfonyl]morpholine) were studied in rat. 2. After s.c. administration of 14C and 13C P903, the Tmax in the blood was observed on day 2. Elimination was slow and > 95% was bound to protein. Radioactivity was distributed in the whole organism but particularly in erythrocytes and the lymphatic channel. Four days later, > 60% of the radioactivity was excreted in urine and faeces at equal amounts and 15% remained at the injection point. 3. In all biological fluids tested no P903 was found but only its metabolites. 4. One principal metabolite, the N-[(2-phenyloxo-2-ethane) sulphonyl] morpholine or oxosulphonamide was identified in blood, urine and faeces as compared with the reference compound by GC/MS and NMR. This latter molecule was detected following hydrolysis by hydrochloric acid but not with beta glucuronidase/sulphatase. 5. Unconjugated and conjugated oxosulphonamide represented > 85% of the radioactivity at all times tested in blood but only 38 and 35% respectively of urinary and faecal radioactivity on day 1 after the administration of the labelled drug. 6. Thus, P903 is rapidly converted to a reactive metabolite, probably an oxirene, which is then conjugated with endogenous components to form conjugated oxosulphonamide and an unknown metabolite. The role of this reactive metabolite in antifilarial activity seems to be very important in understanding the mechanism of action of P903.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041680     DOI: 10.1080/004982597240776

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  1 in total

1.  Crystal structure of methyl (2Z)-2-{[N-(2-formyl-phen-yl)-4-methyl-benzene-sulfonamido]-meth-yl}-3-(4-meth-oxy-phen-yl)prop-2-enoate.

Authors:  Ankur Trigunait; Kannan Damodharan; Bakthadoss Manickam; Gunasekaran Krishnasamy
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.